Email this article Direct oral anticoagulants in atrial fibrillation patients aged 75 years or older: Efficacy and safety balance
- Authors: Fomin VV1, Svistunov AA1, Napalkov DA1, Sokolova AA1, Gabitova MA1
-
Affiliations:
- ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России
- Issue: Vol 89, No 4 (2017)
- Pages: 4-7
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32150
- DOI: https://doi.org/10.17116/terarkh20178944-7
- ID: 32150
Cite item
Full Text
Abstract
Atrial fibrillation (AF) is one of the most common heart rhythm disorders in the population. Researchers revealed a direct relationship between their incidence and a patient’s age long ago. One of the most challenging issues of clinical practice in patients with AF is anticoagulant therapy used in the so-called very elderly patients aged 75 years and older when age itself is a risk factor for developing both thromboembolic and hemorrhagic events due to anticoagulants, regardless of the mechanism of action of the latter. However, scientific data regarding the treatment and prevention of thromboembolic events in elderly and senile patients with AF are very scarce and often uninformative. The data from the EURObservational Research Programme-Atrial Fibrillation Registry Pilot Phase (EORP-AF Pilot) and the randomized clinical studies RELY, ROCKET AF, ARISTOTLE, and AVERROES were analyzed to identify the most safe and most effective anticoagulant for elderly patients (over 75 years). Relying on the analyses of literature data, the authors propose an algorithm based on clinical characteristics for choosing the anticoagulant for patients older than 75 years.
Full Text
##article.viewOnOriginalSite##About the authors
V V Fomin
ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
A A Svistunov
ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
D A Napalkov
ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
A A Sokolova
ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
M A Gabitova
ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
References
- Филатов А.Г., Тарашвили Э.Г. Эпидемиология и социальная значимость фибрилляции предсердий. ФГБУ «Научный центр сердечно-сосудистой хирургии им. А.Н. Бакулева РАМН». М.; 2012.
- Рекомендации. Диагностика и лечение фибрилляции предсердий. Российское кардиологическое общество, Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции, Ассоциация сердечно-сосудистых хирургов. М.; 2012.
- Paul A Heidenreich, Penelope Solis, Mark Estes III NA, Gregg C Fonarow, Corrine Y Jurgens, Joseph E Marine, David D McManus, Robert L McNamara. FACC — ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial FlutterJ Am Coll Cardiol. 2016. doi: 10.1016/j.jacc.2016.03.521
- EHRA PRACTICAL GUIDE / Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation / Updated European Heart Rhythm Association, European society of cardiology — Europace. doi: 10.1093/europace/euv309
- Lip GYH, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJGM, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP and Borani G. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EUROobservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot Registry). Eur Heart J. 2014;35:3365-3376.
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular AF. N Engl J Med. 2011;365:883-891.
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, t al. Apixaban versus warfarin in patients with AF. N Engl J Med. 2011;365:981-992.
- Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, et al. Apixaban in patients with AF. N Engl J Med. 2011;364:806-817.
- Ng KH, Hart RG, Eikelboom JW. Anticoagulation in patients with atrial fibrillation: role of novel oral anticoagulants. Cardiol Ther. 2013;2:135-149.
- Напалков Д.А., Соколова А.А. Алгоритм индивидуального выбора нового перорального антикоагулянта у пациентов с неклапанной фибрилляцией предсердий на основе имеющейся доказательной базы. Эффективная фармакотерапия. 2015;34:24-30.
